How should we proceed with disease-modifying treatments for multiple sclerosis?

Lancet

Volumn 349, Issue 9052, 1997, Pages 586-587

  Andersson, P B ^a   Waubant, E ^a   Goodkin, D E ^a  

^a UCSF Multiple Sclerosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM;

AUSTRALIA; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY; SOCIOECONOMICS; UNEMPLOYMENT; UNITED KINGDOM; UNITED STATES;

EID: 0031040578     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61562-0     Document Type: Note

References (7)

1. G Dean How many people in the world have multiple sclerosis? Neuroepidemiology 13 1994 1 7
2. RA Rudick W Sibley L Durelli Treatment of multiple sclerosis with type 1 interferons DE Goodkin RA Rudick Multiple sclerosis: advances in clinical trial design, treatment and future perspectives 1996 Springer-Verglag London 223 250
3. KP Johnson MB Bornstein Treatment of multiple sclerosis with copolymer-1 DE Goodkin RA Rudick Multiple sclerosis: advances in clinical trial design, treatment and future perspectives 1996 Springer-Verlag London 289 312
4. JF Kurtzke Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
5. DE Goodkin R Rudick S Vanderbrug Medendorp Low-dose (7·5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann Neurol 37 1995 30 40
6. JF Fischer Use of neuropsychologic outcome measures in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design DE Goodkin RA Rudick Multiple sclerosis: advances in clinical trial design, treatment and future perspectives 1996 Springer-Verlag London 123 144
7. NG LaRocca P Ritvo DM Miller “Quality of life” assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design DE Goodkin RA Rudick Multiple sclerosis: advances in clinical trial design, treatment and future perspectives 1996 Springer-Verlag London 145 160